No-observed-adverse-effect-level (NOAEL) assessment as an optimized dose of cholinesterase reactivators for the treatment of exposure to warfare nerve agents in mice.
In: Chemico-biological interactions, Jg. 392 (2024-04-01), S. 110929
Online
academicJournal
Zugriff:
Despite the international convention on the prohibition of chemical weapons ratified in 1997, the threat of conflicts and terrorist attacks involving such weapons still exists. Among these, organophosphorus-nerve agents (OPs) inhibit cholinesterases (ChE) causing cholinergic syndrome. The reactivation of these enzymes is therefore essential to protect the poisoned people. However, these reactivating molecules, mainly named oximes, have major drawbacks with limited efficacy against some OPs and a non-negligible ChE inhibitor potential if administered at an inadequate dose, an effect that they are precisely supposed to mitigate. As a result, this project focused on assessing therapeutic efficacy, in mice, up to the NOAEL dose, the maximum dose of oxime that does not induce any observable toxic effect. NOAEL doses of HI-6 DMS, a reference oxime, and JDS364. HCl, a candidate reactivator, were assessed using dual-chamber plethysmography, with respiratory ventilation impairment as a toxicity criterion. Time-course modeling parameters and pharmacodynamic profiles, reflecting the interaction between the oxime and circulating ChE, were evaluated for treatments at their NOAEL and higher doses. Finally, the therapeutic potential against OPs poisoning was determined through the assessment of protective indices. For JDS364. HCl, the NOAEL dose corresponds to the smallest dose inducing the most significant therapeutic effect without causing any abnormality in ChE activity. In contrast, for HI-6 DMS, its therapeutic benefit was observed at doses higher than its NOAEL, leading to alterations in respiratory function. These alterations could not be directly correlated with ChE inhibition and had no adverse effects on survival. They are potentially attributed to the stimulation of non-enzymatic cholinergic targets by HI-6 DMS. Thus, the NOAEL appears to be an optimal dose for evaluating the efficacy of oximes, particularly when it can be linked to respiratory alterations effectively resulting from ChE inhibition.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Calas reports financial support was provided by French Government Ministry of the Armed Forces. Baati reports financial support was provided by French National Research Agency. Baati has patent Broad spectrum reactivators of OPNA-inhibition of human cholinesterases licensed to CNRS and French Government Ministry of the Armed Forces. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
Titel: |
No-observed-adverse-effect-level (NOAEL) assessment as an optimized dose of cholinesterase reactivators for the treatment of exposure to warfare nerve agents in mice.
|
---|---|
Autor/in / Beteiligte Person: | Trancart, M ; Hanak, AS ; Dambrune, C ; Madi, M ; Voros, C ; Baati, R ; Calas, AG |
Link: | |
Zeitschrift: | Chemico-biological interactions, Jg. 392 (2024-04-01), S. 110929 |
Veröffentlichung: | Limerick : Elsevier ; <i>Original Publication</i>: Amsterdam, Elsevier., 2024 |
Medientyp: | academicJournal |
ISSN: | 1872-7786 (electronic) |
DOI: | 10.1016/j.cbi.2024.110929 |
Schlagwort: |
|
Sonstiges: |
|